Search Result

Results for "

lymphoblastic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (3) ADC Payload (7) Akt (3) Aldose Reductase (1) AMPK (2) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (1) Antifolate (8) Apoptosis (68) Atg8/LC3 (2) Autophagy (5) Bacterial (6) Bcl-2 Family (4) Bcr-Abl (10) c-Myc (1) Calcium Channel (2) Caspase (5) CD19 (3) CD22 (3) CD3 (1) CD47 (2) CDK (9) CXCR (1) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (1) Deubiquitinase (2) Dihydrofolate reductase (DHFR) (1) Discoidin Domain Receptor (1) DNA Alkylator/Crosslinker (2) DNA/RNA Synthesis (26) Drug Derivative (3) Drug Isomer (2) Drug Metabolite (2) E1/E2/E3 Enzyme (1) Endogenous Metabolite (20) Epigenetic Reader Domain (8) ERK (2) Eukaryotic Initiation Factor (eIF) (2) FGFR (2) FLT3 (3) Fluorescent Dye (1) Fungal (1) Galectin (1) Glucocorticoid Receptor (1) Glutathione Peroxidase (2) Glutathione S-transferase (1) HDAC (5) Histamine Receptor (4) Histone Acetyltransferase (1) Histone Demethylase (5) Histone Methyltransferase (1) HSP (1) HSV (1) IFNAR (3) Insecticide (1) Insulin Receptor (1) Integrin (1) Interleukin Related (8) IRAK (1) Isotope-Labeled Compounds (16) JAK (2) Ligands for E3 Ligase (1) MAP4K (1) MDM-2/p53 (4) MEK (1) Microtubule/Tubulin (9) Mitochondrial Metabolism (3) Mitosis (6) Molecular Glues (5) mTOR (1) NEKs (1) NF-κB (1) NO Synthase (1) NOD-like Receptor (NLR) (1) Notch (6) Nucleoside Antimetabolite/Analog (4) p38 MAPK (2) PARP (4) PD-1/PD-L1 (3) PDK-1 (1) Photosensitizer (1) PI3K (5) Platelet-activating Factor Receptor (PAFR) (1) PROTACs (18) Proteasome (1) Reactive Oxygen Species (ROS) (1) Reference Standards (11) RIP kinase (1) SARS-CoV (2) Sec61 (2) SHMT (1) Sirtuin (1) Src (7) STAT (2) TAM Receptor (1) Thrombopoietin Receptor (1) Thymidylate Synthase (1) TNF Receptor (3) Topoisomerase (1) Transmembrane Glycoprotein (3) Wee1 (1) γ-secretase (2)
By Research Areas:	Cancer (154) Cardiovascular Disease (4) Endocrinology (2) Infection (6) Inflammation/Immunology (40) Metabolic Disease (12) Neurological Disease (13)
Click Chemistry:	PROTAC Synthesis (1)
Oligonucleotides:	Nucleoside Analogs (2) Solubilizing Agents (1) Freeze-drying Protective Agents (1) Cytidine (2)

170

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14519

Methotrexate Maximum Cited Publications 76 Publications Verification Amethopterin; CL14377; WR19039	Antifolate DNA/RNA Synthesis ADC Payload Apoptosis Bacterial	Infection Neurological Disease Inflammation/Immunology Cancer
Methotrexate (Amethopterin), an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia) .

HY-136175

Revumenib 10+ Cited Publications SNDX-5613	Epigenetic Reader Domain	Cancer
Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding K_i of 0.149 nM and a cell based IC₅₀ of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .

HY-P9963

Blinatumomab 2 Publications Verification bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO	CD19	Cancer
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .

HY-P1923

L-Asparaginase 10+ Cited Publications L-ASNase	Apoptosis DNA/RNA Synthesis	Cancer
L-Asparaginase (L-ASNase) is a deamidating enzyme that catalyses the hydrolysis of L-asparagine and L-glutamine, and can be used for the research of acute lymphoblastic leukemia. L-Asparaginase depletes L-asparagine from plasma resulting in inhibition of RNA and DNA synthesis with the subsequent blastic cell apoptosis .

HY-N0488A

Vincristine Maximum Cited Publications 74 Publications Verification Leurocristine; NSC-67574; 22-Oxovincaleukoblastine	Apoptosis Microtubule/Tubulin Mitosis	Infection Cancer
Vincristine (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a K_i of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas .

HY-148026

Sonrotoclax BGB 11417	Bcl-2 Family	Cancer
Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines .

HY-14519A

Methotrexate disodium Maximum Cited Publications 76 Publications Verification Amethopterin disodium; CL14377 disodium; WR19039 disodium	Antifolate DNA/RNA Synthesis ADC Payload Apoptosis Bacterial	Inflammation/Immunology Cancer
Methotrexate (Amethopterin) disodium, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate disodium, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia) .

HY-P99412

Lusvertikimab 1 Publications Verification OSE-127	Interleukin Related	Cancer
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .

HY-112654

GCN2iB 55+ Cited Publications	Eukaryotic Initiation Factor (eIF) Glutathione Peroxidase	Cardiovascular Disease Metabolic Disease Cancer
GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC₅₀ of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy .

HY-174228

I3IN-002	Insulin Receptor Apoptosis	Cancer
I3IN-002 is a small-molecule RNA-binding protein IGF2BP3 inhibitor with an IC₅₀ value of approximately 2 μM in SEM cells. I3IN-002 interferes with interaction with m6 A-modified mRNAs, disrupting the stabilization of target genes (such as CDK6, MYC, and BCL2) to inhibit leukemic cell growth, induce cell cycle arrest, and promote apoptosis. I3IN-002 is promising for research of B-cell acute lymphoblastic leukemia .

HY-117596

UNC569 2 Publications Verification	TAM Receptor	Cancer
UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC₅₀ of 2.9 nM and a K_i of 4.3 nM. UNC569 also inhibits Axl and Tyro3 with IC₅₀s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research

HY-13701

Nelarabine 3 Publications Verification 506U78; GW 506U78; Nelzarabine	Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Nelarabine (506U78) is a nucleoside analogue and can be used for the research of T cell acute lymphoblastic leukemia (T-ALL) .

HY-172162

LC-04-045	Molecular Glues NEKs Interleukin Related	Inflammation/Immunology Cancer
LC-04-045 is a selective NIMA-related kinase 7 (NEK7) molecular glue degrader. LC-04-045 induces NEK7 degradation via the CRBN-based ubiquitin-proteasome system, dependent on the glycine 57-containing degron motif. LC-04-045 inhibits secretion of downstream cytokines IL-1β and IL-18. LC-04-045 can be used for the research of lymphoblastic leukemia .

HY-14519S

Methotrexate-d3	Antifolate DNA/RNA Synthesis ADC Payload Apoptosis	Inflammation/Immunology Cancer
Methotrexate-d₃ (Amethopterin-d₃) is the deuterium labeled Methotrexate. Methotrexate (Amethopterin), an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia) .

HY-104010A

Asciminib hydrochloride 10+ Cited Publications ABL001 hydrochloride	Bcr-Abl	Cancer
Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC₅₀ of 0.25 nM .

HY-148530

YX-2-107	PROTACs CDK	Cancer
YX-2-107 is a PROTAC (IC₅₀= 4.4 nM) that selectively degrades CDK6. YX-2-107 effectively inhibits RB phosphorylation and FOXM1 expression in vitro and inhibits the development of Ph ⁺ ALL in rats. YX-2-107 can be used in the study of Ph chromosome-positive (Ph ⁺) acute lymphoblastic leukemia (ALL) .

HY-156794

Enzomenib DSP-5336	Epigenetic Reader Domain FLT3	Cancer
Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC₅₀=1.4 nM, K_d=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations .

HY-103688

N-Ac-γ-Calicheamicin-AcBut-NHS ester	ADC Payload	Cancer
AcBut-N-Ac-γ-Calicheamicin is an ADC cytotoxic payload that induces cell cycle arrest and apoptosis by causing DNA double-strand breaks. AcBut-N-Ac-γ-Calicheamicin is primarily used in the synthesis of antibody-drug conjugates (ADC) and holds promise for research in the field of cancer, including acute lymphoblastic leukemia (ALL) and other hematological malignancies .

HY-P99285

Denintuzumab 1 Publications Verification hBU 12	ADC Antibody CD19	Cancer
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .

HY-17564

2'-Deoxycytidine hydrochloride 5+ Cited Publications 2'-Deoxycytidine monohydrochloride; Deoxycytidine hydrochloride; NSC 83251	Endogenous Metabolite Nucleoside Antimetabolite/Analog	Cancer
2'-Deoxycytidine hydrochloride is an orally effective nucleic acid biosynthesis enzyme inhibitor. 2'-Deoxycytidine hydrochloride competes with nucleic acid biosynthesis enzymes and nucleoside transporters, thereby reducing the toxicity of cytarabine. 2'-Deoxycytidine (hydrochloride) can be used in the research of L1210 lymphoblastic leukemia .

HY-176244

KI-TOX-A3	Histone Acetyltransferase	Cancer
KI-TOX-A3 is a TOX protein-protein interaction inhibitor that blocks the TOX-KAT7 protein-protein interaction with an IC₅₀ of 0.51 μM. KI-TOX-A3 induces proteasomal degradation of TOX, restores KAT7-mediated H3K14 acetylation, reverses exhaustion of CD8 ⁺ T cells, and inhibits the proliferation of T cell acute lymphoblastic leukemia (T-ALL) cells. KI-TOX-A3 shows promise for use in studies of hematological malignancies such as T-ALL .

HY-N0097A

9-β-D-Arabinofuranosylguanine AraG	Drug Derivative	Cancer
9-β-D-Arabinofuranosylguanine is a Guanosine (HY-N0097) analog and shows high affinity for deoxyguanosine kinase (dGK) with a K_m of 8.0 μM. 9-β-D-Arabinofuranosylguanine can be used for the research of T-cell lymphoblastic disease .

HY-124573

(R)-Odafosfamide OBI-3424; TH-3424; (R)-AST-3424	DNA Alkylator/Crosslinker	Cancer
(R)-Odafosfamide (OBI-3424) is a proagent that is selectively converted by AKR1C3 (aldo-keto reductase 1C3) to a potent DNA-alkylating agent. (R)-Odafosfamide can be used for hepatocellular carcinoma, castrate-resistant prostate cancer, and acute lymphoblastic leukemia (ALL) research .

HY-150109

Purinostat mesylate	HDAC Apoptosis	Cancer
Purinostat mesylate is a selective inhibitor of HDAC. Purinostat mesylate inhibits class I and class IIb HDACs with IC₅₀s from 0.81 to 11.5 nM. Purinostat mesylate induces apoptosis and affects cell cycle of LAMA84 and 188 BL-2 cells, and shows potently anti-leukemia effects in vivo. Purinostat mesylate can be used for the research of lymphoblastic leukemia .

HY-N0913

Manninotriose 1 Publications Verification	Antifolate Thymidylate Synthase	Cancer
Manninotriose is a binder of dihydrofolate reductase and thymidylate synthase. Manninotriose binds to dihydrofolate reductase via hydrogen bond formation with Arg28. Manninotriose binds to thymidylate synthase via hydrogen bond formation with Arg50. Manninotriose acts as a membrane protectant and helps improve stress tolerance. Manninotriose can be used in research related to acute lymphoblastic leukemia .

HY-168654

WEE1 degrader 1	Wee1	Cancer
WEE1 degrader 1 (Compound 10) is a CRBN-dependent molecular glue degrader of WEE1 and casein kinase 1α (CK1α) with sub-2 nM DC₅₀ values for both targets. WEE1 degrader 1 can be used for the research of acute lymphoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, colorectal adenocarcinoma, diffuse large b cell lymphoma .

HY-151902

SJ988497	PROTACs JAK	Cancer
SJ988497 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL) .

HY-14174

MRK-560 4 Publications Verification	γ-secretase	Neurological Disease Cancer
MRK-560, a chemical probe, is an orally active, brain barrier-penetrated γ-Secretase inhibitor, reducing Aβ peptide in rat brain and cerebrospinal fluid. MRK-560 decreases mutant NOTCH1 processing by selectively inhibiting PSEN1. MRK-560 can be used in studies of Alzheimer's disease and T-cell acute lymphoblastic leukaemia (T-ALL) .

HY-176528

PROTAC ERK5 degrader-1	ERK PROTACs	Cancer
PROTAC ERK5 degrader-1 (compound 2) is a bifunctional ERK5 PROTAC degrader. PROTAC ERK5 degrader-1 induces ERK5 degradation via VHL-mediated proteasome pathway in MOLT-4 cells. PROTAC ERK5 degrader-1 can be used for the study of a disease or disorder characterized by aberrant ERK5 activity, such as acute lymphoblastic leukemia .

HY-108860

Oncaspar PEG-L-asparaginase; Pegasparaginase	FGFR Interleukin Related	Inflammation/Immunology
Oncaspar (PEG-L-asparaginase; Pegasparaginase), a pegylated form of native Escherichia coli-derived L-asparaginase, breaks down the amino acid asparagine that are circulating in the bloodstream. Oncaspar plays an important role in acute lymphoblastic leukemia (ALL) through asparagine hydrolysis and activation of the integrated stress response (ISR) pathway .

HY-161828

JWZ-5-13	PROTACs CDK	Cancer
JWZ-5-13 is a CDK7 PROTAC degrader. JWZ-5-13 inhibits the proliferation of cancer cells. JWZ-5-13 is applicable to the research of ovarian cancer, diffuse large B-cell lymphoma, acute T-lymphoblastic leukemia and non-small cell lung cancer .

HY-P99650

Grisnilimab WT1	Transmembrane Glycoprotein	Cancer
Grisnilimab (WT1) is an IgG2a monoclonal antibody targeting CD7. Grisnilimab only binds to lymphoid tissues and T lymphocytes, with no off-target binding to normal tissues. Grisnilimab can be used to synthesize the immunotoxin WT1-SMPT-dgRTA, which exerts cytotoxic effects on T-lymphoblastic leukemia cells. Grisnilimab is applicable to relevant research on leukemia .

HY-14519R

Methotrexate (Standard) Amethopterin (Standard); CL14377 (Standard); WR19039 (Standard)	Reference Standards Antifolate DNA/RNA Synthesis ADC Payload Apoptosis Bacterial	Inflammation/Immunology Cancer
Methotrexate (Standard) is the analytical standard of Methotrexate. This product is intended for research and analytical applications. Methotrexate (Amethopterin), an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia) .

HY-N6893

Ergolide 3 Publications Verification	NF-κB NOD-like Receptor (NLR) Apoptosis Autophagy	Neurological Disease Cancer
Ergolide is an orally active dual inhibitor targeting NF-κB/p65 and NLRP3. Ergolide blocks the NF-κB signaling pathway and the nuclear translocation of p65, and irreversibly binds to the NACHT domain of NLRP3 to inhibit inflammasome assembly. Ergolide significantly reduces the production of inflammatory mediators (e.g., NO, PGE₂) and cytokines, induces cancer cell apoptosis, autophagy and ROS generation. Ergolide also enhances the anti-tumor effect of vincristine. Ergolide alleviates acute lung injury via an NLRP3-dependent mechanism, and effectively improves the survival rate and behavioral function of septic mice and inflammatory zebrafish models. Ergolide is used in the research of metastatic uveal melanoma, neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease), sepsis and acute lymphoblastic leukemia .

HY-132997

PROTAC Bcl-xL degrader-3	PROTACs Bcl-2 Family	Cancer
PROTAC Bcl-xL degrader-3 is a potent PROTAC Bcl-xL degrader. PROTAC Bcl-xL degrader-3 forms ternary complexes with the VHL-complex and BCL-XL. PROTAC Bcl-xL degrader-3 can be used in research on acute lymphoblastic leukemia .

HY-171178

DK2403	p38 MAPK	Cancer
DK2403 (compound 25) is a MAP2K7 inhibitor (IC₅₀= 0.01 μM). DK2403 can effectively inhibit MAP2K7 without significantly disrupting the larger kinase group and can be used to study childhood T-cell acute lymphoblastic leukemia .

HY-P99264A

Inotuzumab (powder) Humanized Anti-CD22 Recombinant Antibody (powder)	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma . x

HY-14572

PR-104A SN 27858	DNA Alkylator/Crosslinker Drug Metabolite	Cancer
PR-104A (SN 27858) is the alcohol metabolite of phosphate proagent PR-104. PR-104A is a hypoxia-selective DNA cross-linking agent/DNA-damaging agent and cytotoxin. Antitumor Activity . PR-104A is metabolized under hypoxia by the 1-electron NADPH:cytochrome P450 oxidoreductase. PR-104A can be used for the research of relapsed/refractory T-lineage acute lymphoblastic leukemia (T-ALL) .

HY-12419

BMS-983970	Notch	Cancer
BMS-983970 is an oral pan-Notch inhibitor for the treatment of multiplecancers .

HY-112128

USP7-IN-3 1 Publications Verification	Deubiquitinase MDM-2/p53	Cancer
USP7-IN-3 (Compound 5) is an effective and selective allosteric inhibitor of ubiquitin-specific protease 7 (USP7). USP7-IN-3 can be used for research on acute lymphoblastic leukemia .

HY-P11451

Pentixather	CXCR	Cancer
Pentixather is a radiolabeled peptide that can target CXCR4. Pentixather can disrupt the interaction between leukemic cells and the bone marrow microenvironment by targeting the CXCR4/CXCL12 signaling axis, reduce the retention of leukemic cells in the protective bone marrow niche, and thereby enhance the sensitivity of leukemic cells to treatment. Pentixather can be used for the study of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .

HY-159175

XM-U-14	PROTACs Deubiquitinase Apoptosis MDM-2/p53	Cancer
XM-U-14 is a selective PROTAC USP7 Degrader (DC₅₀: 0.74 nM in inducing USP7 degradation in RS4;11 cell line). XM-U-14 upregulates the levels of p53 and p21. XM-U-14 also significantly inhibits acute lymphoblastic leukemia (ALL) cell growth (IC₅₀: 0.5 nM and 8.3 nM for RS4;11 cells and Reh cells respectively). XM-U-14 induces apoptosis and cycle arrest. XM-U-14 inhibits tumor growth. (Blue: VHL ligand (HY-159465), Black: linker (HY-W539783); Pink: USP7 inhibitor (HY-159464)) .

HY-E70016

Terminal deoxyribonucleotidyltransferase TdT	DNA/RNA Synthesis	Others Cancer
Terminal deoxyribonucleotidyltransferase (TdT) catalyses the condensation of deoxyribonucleotide triphosphates onto the 3' hydroxyl ends of DNA strands and adds N-regions to gene segment junctions during V(D)J recombination. Terminal deoxyribonucleotidyltransferase is expressed in immature, pre-B, pre-T lymphoid cells, and acute lymphoblastic leukemia/lymphoma cells .

HY-162676

SJ45566	PROTACs Src	Cancer
SJ45566 a potent and orally active PROTAC-based LCK degrader, with a DC₅₀ of 1.21 nM. SJ45566 can be used in the research for T‑Cell Acute Lymphoblastic Leukemia .

HY-175463

LCK degrader-2	Molecular Glues Src	Cancer
LCK degrader-2 (Compound 17) is a Lck Molecular glue degrader. LCK degrader-2 can be used for cancers like acute lymphoblastic leukemia (ALL) research .

HY-136522

S2116	Histone Demethylase Apoptosis	Cancer
S2116, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2116 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2116 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2116 significantly retardes the growth of T-ALL cells in xenotransplanted mice .

HY-175281

SJ11646	PROTACs Src Discoidin Domain Receptor Bcr-Abl Apoptosis	Cancer
SJ11646 is a Dasatinib (HY-10181)-based LCK PROTAC degrader with a DC₅₀ of 0.00838 pM. SJ11646 has potent cytotoxicity against LCK-activated T-cell acute lymphoblastic leukemia (T-ALL) cells and primary leukemia samples with drastically prolonged suppression of LCK signaling, and induces T-ALL apoptosis. SJ11646 binds to 51 human kinases with a high affinity (particularly ABL1, KIT, and DDR1). SJ11646 has superior antileukemic efficacy in T-ALL mice model. . Pink: LCK ligand (HY-107447); Blue: CRBN ligase ligand (HY-163169); Black: linker (HY-76667)

HY-175280

Lck degrader-1	Molecular Glues Src	Cancer
Lck degrader-1 (Compound 17) is a molecular glue degrader targeting lymphocyte-specific protein tyrosine kinase (LCK) (DC₅₀=23.1 nM). Lck degrader-1 is promising for research of T-cell acute lymphoblastic leukemia (T-ALL) .

HY-164466

CAD204520	Calcium Channel Notch	Cancer
CAD204520, a SERCA inhibitor (IC₅₀ = 0.34 μM), targets mutated over wild type NOTCH1 proteins in T-cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL). CAD204520 can be used for T-ALL and MCL research .

Cat. No.	Product Name	Type

HY-D2435

MTX-PEG-Cy3

Fluorescent Dye

CDDP-PEG-Cy3 is a MTX-PEG conjugate labeled with Cy3 (HY-D0822). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. The maximum emission wavelength of Cy3 is approximately 562-570 nm. Methotrexate (Amethopterin; MTX) (HY-14519), an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia) .

Cat. No.	Product Name	Target	Research Area

HY-P0132

YIGSR 1 Publications Verification Laminin Fragment 929-933	NO Synthase	Cancer
YIGSR (Laminin Fragment 929-933) is a polypeptide that inhibits tumor growth and metastasis of leukemia cells. YIGSR specifically binds to the 67kDa laminin receptor and regulates the expression of eNOS in endothelial cells. YIGSR can be used in leukemia-related research .

HY-P11451

Pentixather	CXCR	Cancer
Pentixather is a radiolabeled peptide that can target CXCR4. Pentixather can disrupt the interaction between leukemic cells and the bone marrow microenvironment by targeting the CXCR4/CXCL12 signaling axis, reduce the retention of leukemic cells in the protective bone marrow niche, and thereby enhance the sensitivity of leukemic cells to treatment. Pentixather can be used for the study of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .

HY-P10371

PKHB1 txCD47	Reactive Oxygen Species (ROS) Thrombopoietin Receptor Mitochondrial Metabolism HSP HSV CD47	Infection Inflammation/Immunology Cancer
PKHB1 (txCD47) is a CD47 agonist and Thrombospondin-1 peptide mimetic. PKHB1 activates CD47 and triggers Caspase-independent, calcium-dependent cell death via mitochondrial alterations, ROS production, endoplasmic reticulum morphological changes, and dissipation of mitochondrial membrane potential. PKHB1 induces the exposure of Calreticulin, HSP70, and HSP90, thereby driving immunogenic cell death. PKHB1 promotes intratumoral CD8 ⁺T cell infiltration and inhibits breast tumorigenesis. PKHB1 reduces HSV-1 levels and alleviates the severity of herpes simplex keratitis. PKHB1 can be used in research related to breast cancer, herpes simplex keratitis, and T-cell acute lymphoblastic leukemia .

HY-P10466A

KZR-8445 TFA	Sec61 SARS-CoV Interleukin Related TNF Receptor IFNAR	Infection Inflammation/Immunology
KZR-8445 TFA, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 TFA binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 TFA inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 TFA inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 TFA blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 TFA can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection .

HY-P10466

KZR-8445	Sec61 SARS-CoV Interleukin Related TNF Receptor IFNAR	Infection Inflammation/Immunology
KZR-8445, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9963

Blinatumomab 2 Publications Verification bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO	CD19	Cancer
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .

HY-P99412

Lusvertikimab 1 Publications Verification OSE-127	Interleukin Related	Cancer
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .

HY-P99285

Denintuzumab 1 Publications Verification hBU 12	ADC Antibody CD19	Cancer
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .

HY-P99650

Grisnilimab WT1	Transmembrane Glycoprotein	Cancer
Grisnilimab (WT1) is an IgG2a monoclonal antibody targeting CD7. Grisnilimab only binds to lymphoid tissues and T lymphocytes, with no off-target binding to normal tissues. Grisnilimab can be used to synthesize the immunotoxin WT1-SMPT-dgRTA, which exerts cytotoxic effects on T-lymphoblastic leukemia cells. Grisnilimab is applicable to relevant research on leukemia .

HY-P99914

Emfizatamab GNC-038	PD-1/PD-L1 CD19 TNF Receptor CD3 Interleukin Related IFNAR	Inflammation/Immunology Cancer
Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia .

HY-P99264A

Inotuzumab (powder) Humanized Anti-CD22 Recombinant Antibody (powder)	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma . x

HY-P990905

Bexatamig SAR-443579	Interleukin Related	Cancer
Bexatamig (SAR-443579) is a trifunctional natural killer cell engager targeting IL-3R α/CD123, NKp46/NCR1/CD335 and Fc gamma RIIIA/CD16a. Bexatamig forms a cytolytic synapse between natural killer cells and CD123-positive tumor cells. By activating natural killer cells to induce tumor cell death, Bexatamig effectively reduces the burden of CD123-positive acute myeloid leukemia (AML) blasts. Bexatamig has been granted FDA Fast Track designation, and is primarily investigated for relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and high-risk myelodysplastic syndromes .

HY-P991641

IMC-EB10 LY3012218	FLT3 p38 MAPK STAT PI3K Akt	Cancer
IMC-EB10 (LY3012218) is an anti-FLT3 monoclonal antibody. IMC-EB10 binds to FLT3 with high affinity (K_d = 158 pM) and blocks the binding of FLT3 ligand to FLT3 (IC₅₀ ≈ 10 nM), thereby inhibiting MAPK, STAT5, and PI3K/Akt signaling in leukemia cells. IMC-EB10 can enhance the anti-leukemic effect of Methotrexate (HY-14519) and inhibit leukemias expressing wild-type or ITD-mutated FLT3 receptors. IMC-EB10 prolongs the survival of acute lymphoblastic leukemia (ALL) cells and primary leukemia samples and reduces engraftment in non-obese diabetic/severe combined immunodeficiency patients. IMC-EB10 is indicated for leukemia research .

HY-P991328

MAb604.107	Notch	Cancer
MAb604.107 is a human monoclonal antibody (mAb) targeting NOTCH1. MAb604.107 inhibits the proliferation and CD34/CD44 expression of primary T-ALL cells. MAb604.107 has anti-tumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. MAb604.107 can be used in T acute lymphoblastic leukemia research .

HY-P992058

Leukotuximab ART-140; DNP-001; EGX-040	Transmembrane Glycoprotein	Cancer
Leukotuximab (ART-140; EGX-040) is an anti-JL1 mAb and an anti-leukemic agent. Leukotuximab targets the JL1 epitope of CD43 and exerts cytotoxic effects on JL1-positive leukemia cells. Except for thymocytes and some bone marrow mononuclear cells, Leukotuximab causes no damage to most normal tissues. Leukotuximab can be used in the research of acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome .

HY-P991924

CO-1	CD47	Cancer
CO-1 is an IgG4 anti-CD47 antibody. CO-1 not only enhances themacrophage phagocytosis activity but also induces a unique and fast form of programmed celldeath (PCD) in cancer cells directly through ligation of CD47. CO-1 has anticancer activity against hematologic malignancies such as acute lymphoblastic leukemia .

HY-P992275

Anti-Nicastrin Antibody (A5226A)	γ-secretase	Neurological Disease Cancer
Anti-Nicastrin Antibody (A5226A) is a monoclonal antibody against Nicastrin and an inhibitor of γ-secretase. Anti-Nicastrin Antibody (A5226A) recognizes the fully glycosylated mature presenilin enhancer in the active γ-secretase complex and inhibits its activity via competition for substrate binding. Anti-Nicastrin Antibody (A5226A) abrogates the growth of cancer cells dependent on γ-secretase activity. Anti-Nicastrin Antibody (A5226A) serves as an imaging tool to visualize the endocytic trafficking of active γ-secretase, and also acts as a detection reagent to evaluate the endocytic efficiency of γ-secretase. Anti-Nicastrin Antibody (A5226A) can be used in studies related to non-small cell lung cancer, T-cell acute lymphoblastic leukemia and Alzheimer's disease .

HY-P991896

AT1412 AT14-012	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells ^[1] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0488

Vincristine sulfate Maximum Cited Publications 74 Publications Verification Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate	Apocynaceae Alkaloids Structural Classification Classification of Application Fields Anti-aging Plants Disease Research Fields Alkaloid Dimers Catharanthus roseus (L.) G. Don Source Classification Cancer	Apoptosis Microtubule/Tubulin Mitosis
Vincristine (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) sulfate is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a K_i of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas .

HY-N0488A

Vincristine Maximum Cited Publications 74 Publications Verification Leurocristine; NSC-67574; 22-Oxovincaleukoblastine	Apocynaceae Alkaloids Structural Classification Classification of Application Fields Plants Disease Research Fields Alkaloid Dimers Catharanthus roseus (L.) G. Don Source Classification Cancer	Apoptosis Microtubule/Tubulin Mitosis
Vincristine (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a K_i of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas .

HY-N0667

L-Asparagine 5 Publications Verification (-)-Asparagine; Asn; Asparamide	Neurological Disease Classification of Application Fields Amino acids Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite Apoptosis DNA/RNA Synthesis
L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-17564

2'-Deoxycytidine hydrochloride 5+ Cited Publications 2'-Deoxycytidine monohydrochloride; Deoxycytidine hydrochloride; NSC 83251	Structural Classification Natural Products Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Nucleoside Antimetabolite/Analog
2'-Deoxycytidine hydrochloride is an orally effective nucleic acid biosynthesis enzyme inhibitor. 2'-Deoxycytidine hydrochloride competes with nucleic acid biosynthesis enzymes and nucleoside transporters, thereby reducing the toxicity of cytarabine. 2'-Deoxycytidine (hydrochloride) can be used in the research of L1210 lymphoblastic leukemia .

HY-W017443

L-Asparagine monohydrate 5 Publications Verification	Classification of Application Fields Metabolic Disease Amino acids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Apoptosis DNA/RNA Synthesis
L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-N0913

Manninotriose 1 Publications Verification	Structural Classification Polysaccharides other families Classification of Application Fields Other Diseases Plants Disease Research Fields Saccharides Source Classification	Antifolate Thymidylate Synthase
Manninotriose is a binder of dihydrofolate reductase and thymidylate synthase. Manninotriose binds to dihydrofolate reductase via hydrogen bond formation with Arg28. Manninotriose binds to thymidylate synthase via hydrogen bond formation with Arg50. Manninotriose acts as a membrane protectant and helps improve stress tolerance. Manninotriose can be used in research related to acute lymphoblastic leukemia .

HY-N6893

Ergolide 3 Publications Verification	Phyllodium pulchellum (L.) Desv. Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Plants Compositae Inflammation/Immunology Disease Research Fields Piptanthus nepalensis (Hook.) D. Don Source Classification	NF-κB NOD-like Receptor (NLR) Apoptosis Autophagy
Ergolide is an orally active dual inhibitor targeting NF-κB/p65 and NLRP3. Ergolide blocks the NF-κB signaling pathway and the nuclear translocation of p65, and irreversibly binds to the NACHT domain of NLRP3 to inhibit inflammasome assembly. Ergolide significantly reduces the production of inflammatory mediators (e.g., NO, PGE₂) and cytokines, induces cancer cell apoptosis, autophagy and ROS generation. Ergolide also enhances the anti-tumor effect of vincristine. Ergolide alleviates acute lung injury via an NLRP3-dependent mechanism, and effectively improves the survival rate and behavioral function of septic mice and inflammatory zebrafish models. Ergolide is used in the research of metastatic uveal melanoma, neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease), sepsis and acute lymphoblastic leukemia .

HY-137129

10-Formyl-7,8-dihydrofolic acid	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Dihydrofolate reductase (DHFR)
10-Formyl-7,8-dihydrofolic acid is a biologically active folic acid and growth promoter. 10-Formyl-7,8-dihydrofolic acid serves as a substrate for aminoimidazolecarboxamide ribonucleotide transformylase and dihydrofolate reductase (DHFR) to support catalytic reactions (with detection wavelengths of 552 nm and 340 nm, respectively). 10-Formyl-7,8-dihydrofolic acid not only promotes the growth of leukemia cells, but also effectively reverses the growth inhibition induced by antifolate drugs under folate-deficient conditions. 10-Formyl-7,8-dihydrofolic acid can be used in the research of leukemia .

HY-N0667R

L-Asparagine (Standard) (-)-Asparagine (Standard); Asn (Standard); Asparamide (Standard)	Structural Classification Immune System Disorder Microorganisms Disease markers Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer Source Classification	Reference Standards Endogenous Metabolite Apoptosis DNA/RNA Synthesis
L-Asparagine (Standard) is the analytical standard of L-Asparagine (HY-N0667). This product is intended for research and analytical applications. L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-N16403

Aspergillusidone F	Structural Classification Natural Products Microorganisms Source Classification	Cytochrome P450 Endogenous Metabolite Bacterial Insecticide Fungal
Aspergillusidone F is a Depsidone and antibacterial agent. Aspergillusidone F can be isolated from a marine fungus Aspergillus unguis. Aspergillusidone F potently inhibits Aromatase with an IC₅₀ of 0.5 μM. Aspergillusidone F exhibits antibacterial activity against Pseudomonas aeruginosa and Methicillin (HY-121544)-resistant Staphylococcus aureus. Aspergillusidone F exhibits potent larvicidal activity against Artemia salina larvae, with an LC₅₀ value of 12.8 μM. Aspergillusidone F exhibits anticancer activity against intrahepatic cholangiocarcinoma, non-small cell lung cancer, and acute lymphoblastic leukemia .

HY-N10777

1-Ketoaethiopinone	Ardisia crenata Sims Terpenoids Diterpenoids Plants Myrsinaceae Source Classification	Others
1-Ketoaethiopinone is an abietane-diterpenoid. 1-Ketoaethiopinone has an α, β-unsaturated carbonyl function. 1-Ketoaethiopinone shows cytotoxic activity against human cancer cell lines MOLT-4 (human lymphoblastic leukemia) and MCF-7 (human breast adenocarcinoma) .

HY-W017443R

L-Asparagine monohydrate (Standard)	Structural Classification Amino acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Apoptosis DNA/RNA Synthesis
L-Asparagine monohydrate (Standard) is the analytical standard of L-Asparagine monohydrate (HY-W017443). This product is intended for research and analytical applications. L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-N0488R

Vincristine sulfate (Standard) Leurocristine sulfate (Standard); NSC-67574 sulfate (Standard); 22-Oxovincaleukoblastine sulfate (Standard)	Apocynaceae Alkaloids Structural Classification Plants Alkaloid Dimers Catharanthus roseus (L.) G. Don Source Classification	Reference Standards Apoptosis Microtubule/Tubulin Mitosis
Vincristine (sulfate) (Standard) is the analytical standard of Vincristine (sulfate). This product is intended for research and analytical applications. Vincristine sulfate (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a K_i of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas .

HY-N3055

Pinusolide	Cupressaceae Classification of Application Fields Terpenoids Diterpenoids Plants Disease Research Fields Calocedrus decurrens (Torr.) Florin Source Classification Cancer	Apoptosis AMPK Platelet-activating Factor Receptor (PAFR) Caspase
Pinusolide is an AMPK activator and PAF receptor antagonist. Pinusolide activates AMPK, phosphorylates ACC, enhances IRS-1 tyrosine phosphorylation, boosts glucose uptake, and modulates insulin signaling. Pinusolide inhibits caspase-3/7 activation, intracellular calcium elevation, reactive oxygen species overproduction, lipid peroxidation, and tumor cell proliferation. Pinusolide stabilizes superoxide dismutase activity, reduces apoptotic hallmarks, induces mitochondrial pathway apoptosis, and triggers DNA fragmentation. Pinusolide can be used for the research of type 2 diabetes, neurodegenerative diseases, acute lymphoblastic leukemia, acute myeloid leukemia, and Burkitt lymphoma .

HY-N17588

9-O-Angeloyl-8-methoxythymol	Structural Classification Phenols Plants Compositae Guilandina minax (Hance) G. P. Lewis Source Classification	Drug Derivative
9-O-Angeloyl-8-methoxythymol (compound 5) is a thymol derivative and cytotoxin, with a IC₅₀ value of 13.1 μg/mL against human myeloid leukemia cells, a IC₅₀ value of 31.8 μg/mL against human lymphoblastic leukemia cells, and a IC₅₀ >40 μg/mL against colon cancer and lymphoma cells.\n9-O-Angeloyl-8-methoxythymol is applicable to leukemia-related research .

HY-N19312

Diospyrin	Quinones Structural Classification Ebenaceae Phenols Polyphenols Benzene Quinones Plants Source Classification	Apoptosis Glutathione S-transferase Topoisomerase
Diospyrin is a dinaphthoquinone anticancer agent with pro-apoptotic (apoptosis) activity, glutathione S-transferase (Glutathione S-transferase) inhibitory activity, and topoisomerase (Topoisomerase) I inhibitory activity. Diospyrin is present in the heartwood of various Diospyros plants and can be used for research on Ehrlich ascites carcinoma, acute myeloid leukemia, chronic myeloid leukemia, mammary adenocarcinoma, cervical epithelial carcinoma, malignant cutaneous melanoma, laryngeal epidermoid carcinoma, human osteosarcoma, and human lymphoblastic carcinoma .

Cat. No.	Product Name	Chemical Structure

HY-14519S

Methotrexate-d3

Methotrexate-d₃ (Amethopterin-d₃) is the deuterium labeled Methotrexate. Methotrexate (Amethopterin), an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia) .

HY-N0667S2

L-Asparagine-15N2 monohydrate

1 Publications Verification

L-Asparagine- ¹⁵N₂ monohydrate is the ¹⁵N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-N0667S5

L-Asparagine-d3 hydrate

1 Publications Verification

L-Asparagine-d₃ hydrate is the deuterium labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-W017443S

L-Asparagine-13C4,15N2 monohydrate

L-Asparagine- ¹³C₄, ¹⁵N₂ monohydrateis the ¹³C-labeled and ¹⁵N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-N0667S3

L-Asparagine-13C4 monohydrate

L-Asparagine- ¹³C₄ monohydrate is the ¹³C-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-N0488S

Vincristine-d3 sulfate

Vincristine-d₃ sulfate is the deuterium labeled Vincristine sulfate. Vincristine sulfate (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a K_i of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas .

HY-W017443S1

L-Asparagine-amide-15N monohydrate

L-Asparagine-amide- ¹⁵N monohydrate is the ¹⁵N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-N0667S7

L-Asparagine-13C4,15N2

L-Asparagine- ¹³C₄, ¹⁵N₂ ((-)-Asparagine- ¹³C₄, ¹⁵N₂) is the ¹³C and ¹⁵N-labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-N0488S2

Vincristine-d6 sulfate

Vincristine-d₆ (sulfate) is the deuterium labeled Vincristine sulfate. Vincristine sulfate (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a K_i of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas .

HY-N0488S1

Vincristine-d3-1 sulfate

Vincristine-d₃ sulfate is the deuterium labeled Vincristine sulfate. Vincristine-1 sulfate (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a K_i of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine-1 sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine-1 sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine-1 sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas .

HY-14519S1

Methotrexate-d3 diammonium

Methotrexate-d₃ diammonium is the deuterium labeled Methotrexate diammonium. Methotrexate (Amethopterin), an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia) .

HY-N0667S1

L-Asparagine-15N2,d8

L-Asparagine- ¹⁵N₂,d₈ is the ¹⁵N- and deuterium labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-N0667S4

L-Asparagine-4-13C monohydrate

L-Asparagine-4- ¹³C monohydrate is the ¹³C-labeled L-Asparagine monohydrate (HY-W017443).L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-W017443S4

L-Asparagine-1,2,3,4-13C4 monohydrate

L-Asparagine-1,2,3,4- ¹³C₄ monohydrate is the ¹³C labeled labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-N0667S

L-Asparagine-13C4,15N2,d8

L-Asparagine- ¹³C₄, ¹⁵N₂,d₈ is the ¹³C-labeled and ¹⁵N-labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-W017443S2

L-Asparagine-13C4,15N2,d3 monohydrate

L-Asparagine- ¹³C₄, ¹⁵N₂,d₃ monohydrate is the deuterium, ¹³C-, and ¹⁵N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-W017443S3

L-Asparagine-15N2,d3 monohydrate

L-Asparagine- ¹⁵N₂,d₃ monohydrate is the deuterium and ¹⁵N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

Cat. No.	Product Name		Classification

HY-137342

SB1-G-187		PROTAC Synthesis
SB1-G-187 is a multi-target kinase PROTAC degrader with activity against various kinases including GCK, YES1, IRAK1 and LYN. SB1-G-187 induces degradation of target kinases via a p97-dependent pathway, and forms ternary complexes with CRBN and specific functional kinases. SB1-G-187 can be used in tumor-related research. (Pink: multi-target kinase ligand (HY-125142); Blue: CRBN ligand (HY-A0003); Black: linker) .

Cat. No.	Product Name		Classification

HY-N0667

L-Asparagine 5 Publications Verification (-)-Asparagine; Asn; Asparamide		Freeze-drying Protective Agents Solubilizing Agents
L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .

HY-17564

2'-Deoxycytidine hydrochloride 5+ Cited Publications 2'-Deoxycytidine monohydrochloride; Deoxycytidine hydrochloride; NSC 83251		Nucleoside Analogs Cytidine
2'-Deoxycytidine hydrochloride is an orally effective nucleic acid biosynthesis enzyme inhibitor. 2'-Deoxycytidine hydrochloride competes with nucleic acid biosynthesis enzymes and nucleoside transporters, thereby reducing the toxicity of cytarabine. 2'-Deoxycytidine (hydrochloride) can be used in the research of L1210 lymphoblastic leukemia .

HY-161080

4'-Ethynyl-2'-deoxycytidine		Nucleoside Analogs Cytidine
4'-Ethynyl-2'-deoxycytidine is an anticancer nucleoside. 4'-Ethynyl-2'-deoxycytidine can used in study acute lymphoblastic leukemia and diffuse large B-cell lymphoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

lymphoblastic

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products